{"hands_on_practices": [{"introduction": "The power of the adaptive immune system lies in its vast and diverse repertoire of T cell receptors (TCRs), enabling it to recognize a near-infinite array of antigens. This practice delves into the molecular engine of this diversity—V(D)J recombination—by guiding you through a quantitative estimation of the number of unique TCR sequences that can be generated. By translating this fundamental biological process into a combinatorial model, you will gain a profound appreciation for the sheer scale of the immune system's anticipatory arsenal. [@problem_id:2773138]", "problem": "A T cell receptor (TCR) β chain complementarity-determining region 3 (CDR3) sequence is generated by somatic recombination that selects one variable segment, one diversity segment, and one joining segment, followed by exonucleolytic deletions at the coding ends and the addition of random nucleotides by terminal deoxynucleotidyl transferase (TdT). Assume the following idealized model for human TCRβ recombination, focusing on the nucleotide-level sequence of the CDR3 region and ignoring palindromic nucleotides, reading frame constraints, stop codons, selection, and any biases:\n- Segment choice: there are $N_V = 48$ variable segments, $N_D = 2$ diversity segments, and $N_J = 13$ joining segments.\n- Deletion patterns: at each of the four coding ends that form the two junctions (the $3^{\\prime}$ end of $V$, the $5^{\\prime}$ and $3^{\\prime}$ ends of $D$, and the $5^{\\prime}$ end of $J$), exonuclease deletion removes $d \\in \\{0,1,2\\}$ nucleotides, independently across ends.\n- Insertion patterns: at each of the two junctions ($V$–$D$ and $D$–$J$), TdT inserts exactly $N = 4$ nucleotides, each nucleotide independently and uniformly chosen from the four deoxyribonucleotides.\n\nUsing only the above facts and assuming statistical independence among all steps, derive from first principles an expression for the total number of unique nucleotide-level TCRβ CDR3 sequences producible by this process, and then evaluate it for the given parameter values to estimate the order of magnitude. Give your final answer as a single power of ten, $10^{k}$, corresponding to the nearest order of magnitude (i.e., choose the integer $k$ that minimizes $|\\log_{10}(X) - k|$ for your computed count $X$). No units are required.", "solution": "We begin by conducting a formal validation of the problem statement.\n\n**Step 1: Extract Givens**\nThe problem provides the following parameters for a simplified model of human T cell receptor (TCR) β chain recombination:\n- Number of variable (V) segments: $N_V = 48$.\n- Number of diversity (D) segments: $N_D = 2$.\n- Number of joining (J) segments: $N_J = 13$.\n- Exonucleolytic deletion: $d \\in \\{0, 1, 2\\}$ nucleotides are removed independently from each of four coding ends ($V_{3'}$, $D_{5'}$, $D_{3'}$, $J_{5'}$).\n- Nucleotide insertion: exactly $N = 4$ nucleotides are inserted independently at each of the two junctions ($V–D$ and $D–J$).\n- Nucleotide composition: each inserted nucleotide is chosen uniformly and independently from the four possibilities.\n- Core assumptions: All recombination events are statistically independent. Biological constraints such as reading frames, stop codons, protein selection, and any statistical biases in segment usage or enzymatic activity are to be ignored.\n\n**Step 2: Validate Using Extracted Givens**\nThe problem is valid. It is scientifically grounded in the accepted molecular mechanism of V(D)J recombination, a fundamental process in adaptive immunity. The parameters provided are realistic for the human TCRβ locus. The problem is well-posed; it supplies all necessary information and assumptions required to derive a unique quantitative answer. The language is objective and precise, defining a tractable combinatorial problem. The simplifications are explicitly stated and are standard for creating a first-order mathematical model of a complex biological system. The problem statement is self-contained, consistent, and does not violate any criteria for invalidity.\n\n**Step 3: Verdict and Action**\nThe problem is deemed valid. We shall proceed to derive the solution from first principles.\n\nThe total number of unique nucleotide sequences for the CDR3 region, denoted by $X$, is determined by the product of the number of possibilities at each independent stage of its generation. This is a direct application of the rule of product for counting. The distinct sources of diversity are: (1) the combinatorial selection of gene segments, (2) the variability introduced by exonucleolytic deletions, and (3) the variability from random nucleotide insertions.\n\n$$X = D_{\\text{segmental}} \\times D_{\\text{deletional}} \\times D_{\\text{insertional}}$$\n\n1.  **Segmental Diversity ($D_{\\text{segmental}}$)**\n    This component of diversity arises from choosing one $V$ segment from the available $N_V$ segments, one $D$ segment from the $N_D$ segments, and one $J$ segment from the $N_J$ segments. Since these choices are independent, the total number of segmental combinations is:\n    $$D_{\\text{segmental}} = N_V \\times N_D \\times N_J$$\n\n2.  **Deletional Diversity ($D_{\\text{deletional}}$)**\n    Deletions occur at four independent coding ends: the $3^{\\prime}$ end of the $V$ segment, the $5^{\\prime}$ and $3^{\\prime}$ ends of the $D$ segment, and the $5^{\\prime}$ end of the $J$ segment. At each of these four sites, the number of nucleotides removed can be $0$, $1$, or $2$. This gives $3$ possible outcomes for each site. Given their independence, the total number of unique deletion patterns is:\n    $$D_{\\text{deletional}} = 3 \\times 3 \\times 3 \\times 3 = 3^4$$\n\n3.  **Insertional Diversity ($D_{\\text{insertional}}$)**\n    Nontemplated nucleotides are added by Terminal deoxynucleotidyl Transferase (TdT) at the two junctions: the $V–D$ junction and the $D–J$ junction. At each junction, exactly $N = 4$ nucleotides are inserted. Each of these four positions can be occupied by any of the four deoxyribonucleotides (A, C, G, T). The number of possible insertion sequences for a single junction is therefore $4^N = 4^4$. As the insertions at the two junctions are independent events, the total insertional diversity is the product of the possibilities at each junction:\n    $$D_{\\text{insertional}} = (4^4) \\times (4^4) = 4^8$$\n\n**Total Sequence Diversity and Evaluation**\nBy combining the contributions from all three sources, we obtain the expression for the total number of unique nucleotide-level CDR3 sequences:\n$$X = (N_V \\times N_D \\times N_J) \\times 3^4 \\times 4^8$$\nWe substitute the given values into this expression:\n$$X = (48 \\times 2 \\times 13) \\times 3^4 \\times 4^8$$\nThe problem requires an estimate of the order of magnitude, given as $10^k$, where $k$ is the integer that minimizes $|\\log_{10}(X) - k|$. This is equivalent to finding the integer closest to the value of $\\log_{10}(X)$. We proceed to calculate this value.\n$$\\log_{10}(X) = \\log_{10}(48 \\times 2 \\times 13 \\times 3^4 \\times 4^8)$$\nUsing the logarithmic identity $\\log(abc) = \\log(a) + \\log(b) + \\log(c)$, we can decompose the expression. For maximal precision, we first decompose the arguments into their prime factors:\n$$48 = 16 \\times 3 = 2^4 \\times 3$$\n$$4^8 = (2^2)^8 = 2^{16}$$\nTherefore, the expression for $X$ becomes:\n$$X = (2^4 \\times 3) \\times 2 \\times 13 \\times 3^4 \\times 2^{16}$$\nCollecting terms with the same base:\n$$X = 2^{(4+1+16)} \\times 3^{(1+4)} \\times 13 = 2^{21} \\times 3^5 \\times 13$$\nNow, we take the base-10 logarithm:\n$$\\log_{10}(X) = \\log_{10}(2^{21} \\times 3^5 \\times 13)$$\n$$\\log_{10}(X) = 21\\log_{10}(2) + 5\\log_{10}(3) + \\log_{10}(13)$$\nUsing the standard approximations $\\log_{10}(2) \\approx 0.30103$ and $\\log_{10}(3) \\approx 0.47712$, and the more precise value $\\log_{10}(13) \\approx 1.11394$:\n$$\\log_{10}(X) \\approx 21(0.30103) + 5(0.47712) + 1.11394$$\n$$\\log_{10}(X) \\approx 6.32163 + 2.38560 + 1.11394$$\n$$\\log_{10}(X) \\approx 9.82117$$\nThe integer $k$ closest to $9.82117$ is $10$, since $|9.82117 - 10| = 0.17883$, which is less than $|9.82117 - 9| = 0.82117$.\nThus, the nearest order of magnitude for the total number of unique sequences is $10^{10}$.", "answer": "$$ \\boxed{10^{10}} $$", "id": "2773138"}, {"introduction": "Upon successful antigen recognition, a T cell undergoes a dramatic transformation from a quiescent sentinel to an active effector, a process fueled by profound metabolic reprogramming. This exercise places you in the role of an immunologist interpreting real experimental data from an extracellular flux analyzer, a key tool in modern immunometabolism. By analyzing the changes in oxygen consumption and extracellular acidification, you will deduce the metabolic state of activated T cells and predict their response to specific metabolic inhibitors, honing your skills in data-driven scientific reasoning. [@problem_id:2773119]", "problem": "A research group uses an extracellular flux analyzer to quantify metabolic reprogramming of primary murine CD8$^{+}$ T cells following T cell receptor (TCR) stimulation. They measure extracellular acidification rate (ECAR; milli-pH units per minute per $10^6$ cells) and oxygen consumption rate (OCR; pmol $\\mathrm{O_2}$/min per $10^6$ cells) at baseline in resting cells and again at $18$ hours after TCR stimulation with adequate costimulation. The following mean values are obtained (mean of $n = 4$ independent donors):\n\n- Resting cells: ECAR $= 10$, OCR $= 100$\n- TCR-stimulated cells ($18$ hours): ECAR $= 70$, OCR $= 110$\n\nTwo inhibitors are considered for acute perturbation experiments:\n- 2-deoxy-D-glucose (2-DG), a non-metabolizable glucose analogue that blocks glycolysis at the level of hexokinase/glucose-6-phosphate isomerization.\n- Oligomycin, a specific inhibitor of the mitochondrial F$_1$F$_0$-ATP synthase (Complex V) that acutely prevents adenosine triphosphate (ATP) synthesis by oxidative phosphorylation.\n\nBased only on the measurements above and established biochemistry of the assays and inhibitors, which option best infers the predominant metabolic pathway usage after TCR stimulation and predicts the immediate sensitivity of the cells’ bioenergetics and proliferation to 2-DG versus oligomycin, including the expected acute direction of change in ECAR and OCR upon inhibitor addition to the TCR-stimulated cells?\n\nA. After TCR stimulation, glycolytic flux predominates over oxidative phosphorylation. Thus, 2-DG will acutely collapse ECAR in the stimulated cells and strongly impair proliferation, while oligomycin will markedly reduce OCR but trigger an acute compensatory increase in ECAR; proliferation is relatively less sensitive to oligomycin in the short term because glycolytic ATP can partially compensate.\n\nB. After TCR stimulation, oxidative phosphorylation predominates over glycolysis. Thus, oligomycin will acutely reduce OCR and ECAR and strongly impair proliferation, while 2-DG will have minimal effect on ECAR or proliferation; ECAR should decrease upon oligomycin addition because lactate export depends on mitochondrial ATP.\n\nC. TCR stimulation leaves the balance between glycolysis and oxidative phosphorylation essentially unchanged; therefore, 2-DG and oligomycin will have similar acute effects, both reducing ECAR and OCR to comparable extents and suppressing proliferation equally.\n\nD. The elevated ECAR after TCR stimulation primarily reflects increased hydration of carbon dioxide from elevated OCR rather than lactate export; therefore, 2-DG will minimally affect ECAR, whereas oligomycin will reduce both OCR and ECAR with little compensatory response in ECAR; proliferation is expected to be equally sensitive to both inhibitors.", "solution": "The problem statement will first be subjected to rigorous validation.\n\n**Step 1: Extract Givens**\n\n- **Cell type:** Primary murine CD8$^{+}$ T cells.\n- **Measurements:** Extracellular acidification rate (ECAR) in milli-pH units per minute per $10^6$ cells, and oxygen consumption rate (OCR) in pmol $\\mathrm{O_2}$/min per $10^6$ cells.\n- **Experimental data (mean of $n = 4$ donors):**\n    - Resting cells: ECAR $= 10$, OCR $= 100$.\n    - TCR-stimulated cells at $18$ hours: ECAR $= 70$, OCR $= 110$.\n- **Inhibitors:**\n    - 2-deoxy-D-glucose (2-DG): Blocks glycolysis.\n    - Oligomycin: Inhibits mitochondrial F$_1$F$_0$-ATP synthase (Complex V).\n- **Objective:** Infer the predominant metabolic pathway after TCR stimulation and predict the immediate effects of 2-DG and oligomycin on the bioenergetics (ECAR, OCR) and proliferation of TCR-stimulated cells.\n\n**Step 2: Validate Using Extracted Givens**\n\n- **Scientific Grounding:** The problem is based on established principles of cellular metabolism, specifically the metabolic reprogramming of T lymphocytes upon activation. The use of extracellular flux analysis to measure OCR (a proxy for oxidative phosphorylation, OXPHOS) and ECAR (a proxy for glycolysis) is a standard, valid technique. The inhibitors, 2-DG and oligomycin, are well-characterized tools with known mechanisms. The observed data—a dramatic increase in ECAR with only a minor change in OCR—is consistent with the known switch to aerobic glycolysis (the \"Warburg effect\") that supports T cell proliferation and effector function. The problem is scientifically sound and factually correct.\n- **Well-Posedness:** The problem provides quantitative data and asks for a logical inference and prediction based on these data and fundamental biochemical principles. A unique conclusion can be derived. The question is clearly formulated.\n- **Objectivity:** The problem is stated in precise, objective language. There is no subjectivity or ambiguity.\n- **Completeness and Consistency:** The information provided is sufficient and internally consistent. It describes a classic immunometabolism experiment without contradictions.\n\n**Step 3: Verdict and Action**\n\nThe problem statement is scientifically sound, well-posed, objective, and complete. It is therefore **valid**. I will proceed to derive the solution.\n\n**Derivation of the Solution**\n\nThe core of this problem lies in interpreting the provided metabolic flux data and understanding the consequences of inhibiting the two major ATP-producing pathways: glycolysis and oxidative phosphorylation.\n\n$1$. **Analysis of Metabolic State:**\n- The extracellular acidification rate (ECAR) is primarily a measure of lactate efflux, which is the end product of aerobic glycolysis. Therefore, ECAR serves as a proxy for the rate of glycolysis.\n- The oxygen consumption rate (OCR) is a direct measure of mitochondrial respiration, as oxygen is the terminal electron acceptor for the electron transport chain (ETC). Therefore, OCR is a measure of OXPHOS activity.\n\n- In **resting cells**, the OCR of $100$ pmol $\\mathrm{O_2}$/min is substantially higher than the ECAR of $10$ milli-pH units/min. This signifies a metabolic state that is predominantly reliant on oxidative phosphorylation for energy production, which is characteristic of quiescent, homeostatic cells.\n\n- In **TCR-stimulated cells**, the ECAR increases dramatically by a factor of $7$ (from $10$ to $70$), while the OCR increases only marginally by a factor of $1.1$ (from $100$ to $110$). This drastic shift indicates a massive upregulation of glycolysis, far exceeding the modest change in OXPHOS. This metabolic switch to high-rate aerobic glycolysis is a hallmark of activated T cells, necessary to provide not only ATP but also the biosynthetic precursors for rapid cell growth and proliferation (e.g., nucleotides, lipids, amino acids).\n- The primary inference is that **after TCR stimulation, glycolytic flux is the predominant and most highly upregulated metabolic pathway**.\n\n$2$. **Prediction of Inhibitor Effects on TCR-Stimulated Cells:**\n\n- **Effect of 2-DG (Glycolysis inhibitor):**\n    - Since glycolysis is the dominant source of ECAR, its inhibition by 2-DG will lead to an immediate and sharp decrease, or \"collapse,\" of the ECAR.\n    - Proliferation of activated T cells is critically dependent on the high flux through the glycolytic pathway for biomass production. Blocking this pathway with 2-DG will, therefore, severely impair proliferation.\n\n- **Effect of Oligomycin (OXPHOS inhibitor):**\n    - Oligomycin inhibits ATP synthase (Complex V). This blockage prevents the flux of protons from the intermembrane space back into the matrix, causing a buildup of the proton-motive force. This hyperpolarization of the mitochondrial inner membrane inhibits the upstream electron transport chain, causing a sharp decrease in oxygen consumption. Thus, oligomycin will **markedly reduce OCR**.\n    - In response to the shutdown of mitochondrial ATP synthesis, metabolically flexible cells with sufficient glycolytic capacity will attempt to compensate by increasing their rate of glycolysis. This phenomenon is known as the \"glycolytic reserve.\" As the stimulated T cells have already massively upregulated their glycolytic machinery, they possess a high capacity for this compensatory response. The result will be an **acute compensatory increase in ECAR** upon oligomycin addition.\n    - Regarding proliferation, while OXPHOS is important, the cell's ability to acutely ramp up glycolysis can partially buffer the energetic crisis. The primary biosynthetic pathway (glycolysis) remains functional. Therefore, in the short term, proliferation is expected to be **less sensitive to oligomycin than to 2-DG**, which directly targets the anabolic hub.\n\n**Evaluation of Options**\n\n-   **Option A:** This option states that glycolytic flux predominates after stimulation. It correctly predicts that 2-DG will collapse ECAR and strongly impair proliferation. It also correctly predicts that oligomycin will reduce OCR while triggering a compensatory increase in ECAR, and that proliferation will be relatively less sensitive to oligomycin in the short term. This aligns perfectly with our derivation.\n    - **Verdict: Correct.**\n\n-   **Option B:** This option incorrectly claims that oxidative phosphorylation predominates. Based on this false premise, it incorrectly predicts minimal effects for 2-DG and an incorrect response to oligomycin (a decrease in ECAR). The rationale provided for the ECAR decrease (\"lactate export depends on mitochondrial ATP\") is biochemically unsound, as glycolysis produces its own ATP which is more than sufficient to power membrane transporters.\n    - **Verdict: Incorrect.**\n\n-   **Option C:** This option claims the metabolic balance is unchanged, which is in direct contradiction to the provided data (ECAR increases $7$-fold, OCR increases $1.1$-fold). Consequently, its prediction of similar effects for both inhibitors is fundamentally flawed. The inhibitors target distinct and, in this state, unequally utilized pathways.\n    - **Verdict: Incorrect.**\n\n-   **Option D:** This option proposes that elevated ECAR is due to $CO_2$ hydration. This is a severe misinterpretation of the data. A $7$-fold increase in ECAR cannot be explained by a mere $10\\%$ ($1.1$-fold) increase in OCR (the source of mitochondrial $CO_2$). The overwhelming contributor to the high ECAR in this context is lactate from glycolysis. All subsequent predictions based on this false premise are therefore invalid, such as the minimal effect of 2-DG and the lack of compensatory ECAR increase after oligomycin addition.\n    - **Verdict: Incorrect.**", "answer": "$$\\boxed{A}$$", "id": "2773119"}, {"introduction": "The hallmark of a successful T cell response is the rapid and massive expansion of antigen-specific clones, creating an army of cells to clear the pathogen. This practice moves from the single-cell level to population dynamics, challenging you to apply a mathematical model of cell growth and death to quantify this clonal expansion. By comparing your model's prediction with empirically observed values, you will explore the power and limitations of quantitative models in describing complex biological phenomena like an immune response. [@problem_id:2773156]", "problem": "In an acute viral infection, a single naive antigen-specific CD8$^{+}$ cytotoxic T lymphocyte (CTL) clone recognizable by its unique T cell receptor (TCR) expands upon encountering antigen on professional antigen-presenting cells. Consider the following biologically grounded scenario for a single epitope-specific clone in a mouse. The total circulating and lymphoid pool of CD8$^{+}$ T cells is $N_{\\mathrm{tot}} = 5 \\times 10^{7}$ cells. The naive precursor frequency for this epitope is $f_{0} = 2.0 \\times 10^{-6}$, so the initial clone size is $N_{0} = f_{0} N_{\\mathrm{tot}}$. During the expansion phase of length $T = 6$ days, each activated cell divides with a constant division time $\\tau_{\\mathrm{div}} = \\tfrac{1}{3}$ day and dies with a per-capita death rate $\\delta = 0.20 \\ \\mathrm{day}^{-1}$. The target peak effector pool for this clone is $E_{\\mathrm{target}} = 2.0 \\times 10^{6}$ cells. Empirical studies of dominant epitope-specific clones in acute infections report an observed fold expansion of $F_{\\mathrm{obs}} = 5.0 \\times 10^{4}$.\n\nUse a continuous-time birth–death model grounded in population dynamics. Assume that the per-capita division rate is related to the division time by $r = \\ln(2)/\\tau_{\\mathrm{div}}$, and that the net growth rate is $r - \\delta$, yielding exponential dynamics $N(t) = N_{0} \\exp\\!\\big((r - \\delta) t\\big)$ during the expansion phase.\n\nTasks:\n- Compute the fold expansion required to reach the target effector pool, $F_{\\mathrm{needed}} = E_{\\mathrm{target}}/N_{0}$.\n- Compute the model-predicted fold expansion over the expansion phase, $F_{\\mathrm{model}} = \\exp\\!\\big((r - \\delta) T\\big)$.\n- Define the comparison metric $Q = F_{\\mathrm{model}}/F_{\\mathrm{obs}}$.\n\nWhat is the value of $Q$? Round your final answer to three significant figures. Provide a dimensionless result (no units).", "solution": "The problem requires the computation of a comparison metric, $Q$, which relates a model-predicted T cell clonal expansion to an empirically observed value. The model is a continuous-time birth-death process. We will proceed by first calculating the necessary intermediate quantities as defined in the problem statement.\n\nThe provided parameters are:\n- Total initial CD8$^{+}$ T cell pool: $N_{\\mathrm{tot}} = 5 \\times 10^{7}$\n- Naive precursor frequency: $f_{0} = 2.0 \\times 10^{-6}$\n- Duration of expansion phase: $T = 6$ days\n- Cell division time: $\\tau_{\\mathrm{div}} = \\frac{1}{3}$ day\n- Per-capita death rate: $\\delta = 0.20 \\ \\mathrm{day}^{-1}$\n- Target peak effector pool size: $E_{\\mathrm{target}} = 2.0 \\times 10^{6}$\n- Observed fold expansion: $F_{\\mathrm{obs}} = 5.0 \\times 10^{4}$\n\nFirst, we determine the initial size of the antigen-specific T cell clone, $N_{0}$.\n$$N_{0} = f_{0} N_{\\mathrm{tot}}$$\nSubstituting the given values:\n$$N_{0} = (2.0 \\times 10^{-6}) \\times (5 \\times 10^{7}) = 10 \\times 10^{1} = 100 \\ \\text{cells}$$\n\nThe problem defines a task to compute the fold expansion required to reach the target effector pool, $F_{\\mathrm{needed}}$.\n$$F_{\\mathrm{needed}} = \\frac{E_{\\mathrm{target}}}{N_{0}}$$\nUsing our calculated $N_{0}$ and the given $E_{\\mathrm{target}}$:\n$$F_{\\mathrm{needed}} = \\frac{2.0 \\times 10^{6}}{100} = 2.0 \\times 10^{4}$$\n\nNext, we compute the model-predicted fold expansion, $F_{\\mathrm{model}}$. The dynamics are given by $N(t) = N_{0} \\exp((r - \\delta) t)$, so the fold expansion over a period $T$ is $N(T)/N_{0}$, which is:\n$$F_{\\mathrm{model}} = \\exp((r - \\delta) T)$$\nTo evaluate this, we must first find the per-capita division rate, $r$. It is related to the division time, $\\tau_{\\mathrm{div}}$, by the formula for conversion from a discrete division event to a continuous rate:\n$$r = \\frac{\\ln(2)}{\\tau_{\\mathrm{div}}}$$\nWith $\\tau_{\\mathrm{div}} = \\frac{1}{3} \\ \\mathrm{day}$:\n$$r = \\frac{\\ln(2)}{1/3} = 3 \\ln(2) \\ \\mathrm{day}^{-1}$$\n\nNow, we calculate the net growth rate, $k = r - \\delta$.\n$$k = 3 \\ln(2) - 0.20 \\ \\mathrm{day}^{-1}$$\n\nWe can now compute $F_{\\mathrm{model}}$ using the expansion time $T = 6$ days.\n$$F_{\\mathrm{model}} = \\exp(k T) = \\exp\\left((3 \\ln(2) - 0.20) \\times 6\\right)$$\n$$F_{\\mathrm{model}} = \\exp(18 \\ln(2) - 1.2) = \\exp(\\ln(2^{18})) \\exp(-1.2) = 2^{18} \\exp(-1.2)$$\nEvaluating this expression:\n$$F_{\\mathrm{model}} = 262144 \\times \\exp(-1.2) \\approx 262144 \\times 0.301194$$\n$$F_{\\mathrm{model}} \\approx 78945.8$$\n\nFinally, we compute the comparison metric $Q$, defined as the ratio of the model-predicted expansion to the observed expansion.\n$$Q = \\frac{F_{\\mathrm{model}}}{F_{\\mathrm{obs}}}$$\nSubstituting the values for $F_{\\mathrm{model}}$ and $F_{\\mathrm{obs}} = 5.0 \\times 10^{4}$:\n$$Q = \\frac{78945.8}{5.0 \\times 10^{4}} \\approx 1.578916$$\nRounding the result to three significant figures, as required, we obtain $1.58$. This dimensionless value indicates that the simple exponential growth model predicts an expansion that is approximately $1.58$ times larger than what is typically observed for dominant epitopes.", "answer": "$$\\boxed{1.58}$$", "id": "2773156"}]}